Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
Biopharma companies won’t fully capture the benefits of AI unless they reorganize their R&D units, according to McKinsey.
Original title: “Biopharma R&D needs ‘structural redesign’ to maximize AI impact: report”
Saol Therapeutics is the latest biotech to resubmit for approval of a drug rejected under former FDA Commissioner Marty Makary, following REGENXBIO and Replimune.
Original title: “Saol boards FDA’s resubmission boat, armed with new survival data”
GSK and Alector first partnered in 2021 to advance two antibodies for neurodegenerative diseases. Both assets have since failed to show significant clinical benefit.
Original title: “GSK abandons Alector after back-to-back neuro stumbles”
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is seeking potential licensees interested in further developing or utilizing these Casq2 mouse strains. As a research tool, patent protection is not being pursued for this technology. More information to access these strains can be found here: https://www.jax.org/strain/036291 and https://www.jax.org/strain/ 036290.
Original title: “Government Owned Invention Available for License: Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2”
The National Cancer Institute (NCI) and Frederick National Laboratory for Cancer Research (FNLCR) seek research co-development partners and/or licensees for commercial development of a novel liquid biopsy diagnostic for non-invasive detection of cell-free HPV 6 and 11 DNA for recurrent respiratory papillomatosis (RRP).
Original title: “Government Owned Invention Available for License: Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof”
Stay ahead in 2026 with the latest biotech deals. Discover key collaborations, M&A, and strategic moves shaping the industry's future. Explore the pulse of biotech deals on our dedicated page, featuring only the most notable news of 2026. We meticulously curate and categorize the latest collaborations and M&A activities, ensuring you stay informed about the most significant trends and strategic moves shaping the industry. Looking for new funding opportunities and partnerships?
Original title: “2026 biotech deals tracker: the latest partnerships and M&A”
Chan Zuckerberg Initiative's Biohub will offer new grants to the rare disease community while expanding its AI drug repurposing partnership with Every Cure. The announcement also expands Biohub's partnership with Every Cure, the nonprofit founded by Dr. David Fajgenbaum that uses artificial intelligence to identify opportunities to repurpose existing medicines for diseases with few or no treatment options. Biohub already serves as a foundational philanthropic backer of Every Cure. Malepati said the money helped establish research partnerships and organize the patient and scientific communities around CACANA1A-related disorders, a group of rare, lifelong neurological and genetic conditions. The program is also expanding its partnership with Every Cure, connecting advocacy organizations with AI-identified opportunities to repurpose existing medicines. "I'm thrilled about our expanded partnership — from an initial grant to get started with building our AI platform in 2023, to where we are now," Fajgenbaum said.
Original title: “Chan Zuckerberg Initiative's Biohub to open new rare disease funding round”